The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Open accessAbstract
CONTEXT: Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. OBJECTIVE: To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. DESIGN: Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. INTERVENTIONS: Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). MAIN OUTCOMES MEASURES: The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. RESULTS: On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years. CONCLUSIONS: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although hormone therapy is effective in treating hot flashes, its use is contraindicated for individuals initiating hormone therapy more than 10 years from menopause onset or older than 60 years, and with a history of breast cancer, uterine cancer, thromboembolic, or cardiovascular diseases.10,11,12”
From Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The WHI reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis during 5 years of treatment with conjugated equine estrogen and medroxyprogesterone acetate (Prempro®) [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Yet all of about 90 HIV vaccines that succeeded in animals failed in humans.55”
From The Flaws and Human Harms of Animal Experimentation (2015) · cites this paper as [55]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The increases were followed by equally pointed reductions within a few years, likely reflecting a depletion of prevalent cancers”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredIn the citing paper
“Data from the Women’s Health Initiative (WHI) shows several risks of menopausal hormone therapy among healthy postmenopausal women, including an excess risk of coronary heart disease, stroke, and breast cancer (151).”
From From mitochondria to sarcopenia: role of 17β-estradiol and testosterone (2023) · cites this paper as [151]
In the citing paper
“The recent data of the Women's Health Initiative Study show that the combination of Premarin and Provera (Prempro) causes a 26% increase in the risk of breast cancer at 5.2 yr of follow-up”
In the citing paper
“the recent results of the Women's Health Initiative Study (8) clearly indicate that this compound is not recommended for longterm use in normal women where the stimulatory progestational component could well be predominant.”
In the citing paper
“The most effective treatment of hot flushes is estrogen replacement therapy, but the Women’s Health Initiative Study raised questions about the long-term safety of this treatment (Rossouw et al., 2002).”
From Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes (2013) · cites this paper as Rossouw et al., 2002
In the citing paper
“Estrogen replacement therapy and hormone replacement therapy appear to have a neutral effect on BP, as illustrated by the following observations from 2 large randomized trials.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“The Women’s Health Initiative, a randomized placebo-controlled trial, assessed the effect of estrogen-progestin replacement on outcomes in postmenopausal women211 and found that at 5.2 years hormone replacement therapy produced only a small increase (1.5 mm Hg) in SBP compared with placebo.212”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“Estrogen has also been associated with increased risk of “unusual site” thromboses, as well as arterial thrombosis.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“That same year, data from the Women’s Health Initiative randomized clinical trial showed an increased risk of MI and cardiovascular death in women on MHT (HR 1.29, 95% CI, 1.02–1.63) [97].”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“For example, the hypothesis that the effect of hormone replacement therapy (HRT) on coronary heart disease (CHD) might differ depending on the timing of its use (in relation to menopausal status) was not raised until after results from RCTs were published.47,48”
From Triangulation in aetiological epidemiology (2017) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Calle, E. E., Heath Jr., C. W., Coates, R. J., Liff, J. M., Franceschi, S., Talamini, R., Chantarakul, N., Koetsawang, S., Rachawat, D., Morabia, A., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,450
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,921
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,611
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Research works printed but not linked: 6
- [5]5. Rijpkema AH, van der Sanden AA, Ruijs AH. Ef- fects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Ma- turitas. 1990;12:259-285.
- [18]18. Cox DR. Regression analysis and life tables. J R Stat Soc. 1972;34:187-220.
- [23]23. Writing Group for the PEPI Trial. Effects of estro- gen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995; 273:199-208.
- [25]25. Schulman SP, Thiemann DR, Ouyang P, et al. Ef- fects of acute hormone therapy on recurrent ische- mia in postmenopausal women with unstable an- gina. J Am Coll Cardiol. 2002;39:231-237.
- [29]29. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind controlled trial. Ann Intern Med. 2001; 135:939-953.
- [43]43. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275:1389- 1396.
Cited by
Sorted by citations
Items 201–300 of 1,145
Effects of estrogen plus progestin on health-related quality of life
Hays, J., Ockene, J. K., Brunner, R. L., Kotchen, J. M., Manson, J. E., Patterson, R. E., Aragaki, A. K., Shumaker, S. A., Brzyski, R. G., LaCroix, A. Z., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030311 · Cited by 686
Progesterone induces adult mammary stem cell expansion
Joshi, P. A., Jackson, H. W., Beristain, A. G., Grappa, M. A. D., Mote, P. A., Clarke, C. L., Stingl, J., Waterhouse, P. D., & Khokha, R. (2010) · Nature · doi:10.1038/nature09091 · Cited by 698
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N. F., Braunstein, G. D., Burger, H., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 687
Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease
Pradhan, A. D., Manson, J. E., Rossouw, J. E., Siscovick, D. S., Mouton, C. P., Rifai, N., Wallace, R. B., Jackson, R. D., Pettinger, M. B., & Ridker, P. M. (2002) · JAMA · doi:10.1001/jama.288.8.980 · Cited by 683
Buyon, J. P., Petri, M. A., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Merrill, J. T., Sammaritano, L., Lockshin, M., Alarcón, G. S., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00004 · Cited by 661
Progesterone receptors: form and function in brain
Brinton, R. D., Thompson, R. F., Foy, M. R., Baudry, M., Wang, J., Finch, C. E., Morgan, T. E., Pike, C. J., Mack, W. J., Stanczyk, F. Z., et al. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.02.001 · Cited by 675
Stürmer, T., Joshi, M., Glynn, R. J., Avorn, J., Rothman, K. J., & Schneeweiß, S. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.07.004 · Cited by 668
Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women
Chlebowski, R. T., Wactawski‐Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensão, J. L., Rodabough, R. J., Rosenberg, C. A., Taylor, V. M., Harris, R. E., Chen, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032071 · Cited by 663
Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome
Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T. E., Aragaki, A., Lane, D. S., Dolan, N. C., Paskett, E. D., McTiernan, A., Hubbell, F. A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji064 · Cited by 656
Neuhouser, M. L., Aragaki, A. K., Prentice, R. L., Manson, J. E., Chlebowski, R., Carty, C. L., Ochs-Balcom, H. M., Thomson, C. A., Caan, B. J., Tinker, L. F., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1546 · Cited by 630
The different roles of ER subtypes in cancer biology and therapy
Thomas, C. G., & Gustafsson, J.-Α. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3093 · Cited by 654
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S. S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
The Menopause Transition: Signs, Symptoms, and Management Options
Santoro, N. F., Roeca, C. M., Peters, B. A., & Neal-Perry, G. S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa764 · Cited by 774
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality
Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., et al. (2017) · JAMA · doi:10.1001/jama.2017.11217 · Cited by 663
Estrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00005 · Cited by 633
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies
Larsson, S. C., & Wolk, A. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.556 · Cited by 644
Shrank, W. H., Patrick, A. R., & Brookhart, M. A. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1609-1 · Cited by 654
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A. J., Czoty, P. W., Hart, B. A. ‘., Hopkins, W. D., Hu, S., Miller, L. A., Nader, M. A., et al. (2014) · American Journal of Primatology · doi:10.1002/ajp.22281 · Cited by 649
Fuster, V., & Kelly, B. B. (2010) · Cited by 611
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823b5fee · Cited by 617
Conjugated Equine Estrogens and Coronary Heart Disease
Hsia, J. A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.357 · Cited by 607
Hormone therapy for preventing cardiovascular disease in post-menopausal women
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002229.pub4 · Cited by 612
Menopausal Status and Sleep-disordered Breathing in the Wisconsin Sleep Cohort Study
Young, T., Finn, L., Austin, D., & Peterson, A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1055oc · Cited by 606
Hodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T., Harris, D. W., Johnston, C. C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 600
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
False Discovery Rate–Adjusted Multiple Confidence Intervals for Selected Parameters
Benjamini, Y., & Yekutieli, D. (2005) · Journal of the American Statistical Association · doi:10.1198/016214504000001907 · Cited by 671
Vascular Actions of Estrogens: Functional Implications
Miller, V. M., & DUCKLES, S. P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.08002 · Cited by 608
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A. O., Glimcher, L. H., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 596
The Nurses׳ Health Study: lifestyle and health among women
Colditz, G. A., & Hankinson, S. E. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1608 · Cited by 590
Garofalo, C., & Surmacz, E. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20472 · Cited by 597
Kanis, J. А., McCloskey, E. V., Johansson, H., Ström, O., Borgström, F., Odén, A., & National Osteoporosis Guideline Group (2008) · Osteoporosis International · doi:10.1007/s00198-008-0712-1 · Cited by 594
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C. M., Marjoribanks, J., Lethaby, A. E., Suckling, J. A., & Okonkwo, Q. L. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 587
Lahmann, P. H., Hoffmann, K., Allen, N. E., van Gils, C. H., Khaw, K., Téhard, B., Berrino, F., Tjønneland, A. M., Bigaard, J., Olsen, A., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20315 · Cited by 593
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 579
The role of estrogen and androgen receptors in bone health and disease
Manolagas, S. C., O’Brien, C. A., & Almeida, M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.179 · Cited by 598
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D. L., & Glesby, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 578
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L. J., Banka, C. L., Benjamin, E. J., Berra, K. A., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 582
Waters, D. D., Alderman, E. L., Hsia, J. A., Howard, B. V., Cobb, F. R., Rogers, W. J., Ouyang, P., Thompson, P. D., Tardif, J., Higginson, L., et al. (2002) · JAMA · doi:10.1001/jama.288.19.2432 · Cited by 580
Paruthiyil, S., Parmar, H. R., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 577
The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
Rathbun, S. W. (2009) · Circulation · doi:10.1161/circulationaha.108.841403 · Cited by 576
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones
Asscheman, H., Giltay, E. J., Megens, J. A. J., de Ronde, W., van Trotsenburg, M. A. A., & Gooren, L. J. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1038 · Cited by 570
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 567
Gordon, C., Li, C. K., & Isenberg, D. A. (2010) · Medicine · doi:10.1016/j.mpmed.2009.10.006 · Cited by 565
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Chlebowski, R. T., Anderson, G. L., Gass, M. L. S., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J. K., Sarto, G. E., et al. (2010) · JAMA · doi:10.1001/jama.2010.1500 · Cited by 565
Zhu, D., Chung, H., Dobson, A. J., Pandeya, N., Giles, G. G., Bruinsma, F., Brunner, E. J., Kuh, D. J., Hardy, R., Avis, N. E., et al. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30155-0 · Cited by 589
Gibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., DEEDWANIA, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000047041.66447.29 · Cited by 566
Estrogen and cognitive functioning in women
Sherwin, B. B. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0016 · Cited by 560
Nonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006) · JAMA · doi:10.1001/jama.295.17.2057 · Cited by 4
Biomedicalization: Technoscientific Transformations of Health, Illness, and U.S. Biomedicine
Clarke, A. E., Shim, J. K., Mamo, L., Fosket, J. R., & Fishman, J. R. (2003) · American Sociological Review · doi:10.1177/000312240306800201 · Cited by 560
Pischon, T., Lahmann, P. H., Boeing, H., Friedenreich, C., Norat, T., Tjønneland, A., Halkjaer, J., Overvad, K., Clavel-Chapelon, F., Boutron-Ruault, M.-C., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj246 · Cited by 554
Epidemiology of colorectal cancer
Boyle, P., & Leon, M. E. (2002) · British Medical Bulletin · doi:10.1093/bmb/64.1.1 · Cited by 552
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study
Rocca, W. A., Grossardt, B. R., de Andrade, M., Malkasian, G. D., & Melton, L. J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70869-5 · Cited by 548
Ballestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., & Lonardo, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0556-1 · Cited by 570
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544
Beyond the intention-to-treat in comparative effectiveness research
Hernán, M. A., & Hernández-Díaz, S. (2012) · Clinical Trials · doi:10.1177/1740774511420743 · Cited by 528
Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002978.pub2 · Cited by 543
Anderson, G. L. (2003) · JAMA · doi:10.1001/jama.290.13.1739 · Cited by 541
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Sacco, R. L., Adams, R. J., Albers, G. W., Alberts, M. J., Benavente, O., Furie, K. L., Goldstein, L. B., Gorelick, P. B., Halperin, J. L., Harbaugh, R. E., et al. (2006) · Circulation · doi:10.1161/circ.113.10.e409 · Cited by 539
Primary ovarian insufficiency: a more accurate term for premature ovarian failure
Welt, C. K. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03073.x · Cited by 545
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed Central · Cited by 536
Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature
Messina, M. (2016) · Nutrients · doi:10.3390/nu8120754 · Cited by 537
Why Test for Proportional Hazards?
Stensrud, M. J., & Hernán, M. Á. (2020) · JAMA · doi:10.1001/jama.2020.1267 · Cited by 529
The Flaws and Human Harms of Animal Experimentation
AKHTAR, A. (2015) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180115000079 · Cited by 527
Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality
Evans, D. M., & Smith, G. D. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050016 · Cited by 529
Cuzick, J. M., Forbes, J., Šestak, I., Cawthorn, S., Hamed, H., Holli, K. A., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 531
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis
Zhao, L., Jiang, H., Papasian, C. J., Maulik, D., Drees, B. M., Hamilton, J., & Deng, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070813 · Cited by 529
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Sex differences in cognitive impairment and Alzheimer’s disease
Li, R., & Singh, M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.002 · Cited by 527
Nordanstig, J., Behrendt, C., Baumgärtner, I., Belch, J. J. F., Bäck, M., Fitridge, R., Hinchliffe, R. J., Lejay, A., Mills, J. L., Rother, U., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 575
Dietary phytoestrogens and health
Cornwell, T. (2004) · Phytochemistry · doi:10.1016/j.phytochem.2004.03.005 · Cited by 530
Study Design, Precision, and Validity in Observational Studies
Carlson, M. D. A., & Morrison, R. S. (2009) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9690 · Cited by 517
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui, X.-J., Schiff, R., Arpino, G., Osborne, C., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 527
European cancer mortality predictions for the year 2013
Malvezzi, M., Bertuccio, P., Levi, F., Vecchia, C. L., & Negri, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt010 · Cited by 514
Dickersin, K. (2003) · JAMA · doi:10.1001/jama.290.4.516 · Cited by 512
Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause
Sullivan, S. D., Sarrel, P. M., & Nelson, L. M. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.046 · Cited by 519
Davis, S. R., Lambrinoudaki, I. V., Lumsden, M.-A., Mishra, G. D., Pal, L., REES, M. C. P., Santoro, N. F., & Simoncini, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.4 · Cited by 506
Effects of Estrogen With and Without Progestin on Urinary Incontinence
Hendrix, S. L. (2005) · JAMA · doi:10.1001/jama.293.8.935 · Cited by 504
Exploring Sex and Gender Differences in Sleep Health: A Society for Women's Health Research Report
Mallampalli, M. P., & Carter, C. L. (2014) · Journal of Women's Health · doi:10.1089/jwh.2014.4816 · Cited by 504
Understanding breast cancer risk - where do we stand in 2005?
Dumitrescu, R., & Cotarla, I. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00350.x · Cited by 502
Jørgensen, K. J., & Gøtzsche, P. C. (2009) · BMJ · doi:10.1136/bmj.b2587 · Cited by 502
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 522
Estrogen Signaling and Cardiovascular Disease
Murphy, E. (2011) · Circulation Research · doi:10.1161/circresaha.110.236687 · Cited by 515
Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases
Kander, M. C., Cui, Y., & Liu, Z. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13038 · Cited by 497
Ververidis, F., Trantas, E., Douglas, C. J., Vollmer, G., Kretzschmar, G., & Panopoulos, N. J. (2007) · Biotechnology Journal · doi:10.1002/biot.200700084 · Cited by 505
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
Harvey, J. A., & Bovbjerg, V. E. (2004) · Radiology · doi:10.1148/radiol.2301020870 · Cited by 491
Sex-specific differences in hypertension and associated cardiovascular disease
Colafella, K. M. M., & Denton, K. M. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.189 · Cited by 505
Estrogen and the cardiovascular system
Knowlton, A. A., & Lee, A. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.007 · Cited by 490
Hormone-replacement therapy: current thinking
Lobo, R. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.164 · Cited by 526
Evidence from randomised trials on the long-term effects of hormone replacement therapy
Beral, V., Banks, E., & REEVES, G. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11032-4 · Cited by 484
Modulation of Antioxidant Enzyme Expression and Function by Estrogen
Strehlow, K., Rotter, S., Wassmann, S., Adam, O., Grohé, C., Laufs, K., Böhm, M., & Nickenig, G. (2003) · Circulation Research · doi:10.1161/01.res.0000082334.17947.11 · Cited by 483
Cardiovascular Safety of Testosterone-Replacement Therapy
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S. S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215025 · Cited by 514
Hippisley‐Cox, J., & Coupland, C. A. C. (2009) · BMJ · doi:10.1136/bmj.b4229 · Cited by 493
Phytoestrogens: a review of the present state of research
Ososki, A. L., & Kennelly, E. J. (2003) · Phytotherapy Research · doi:10.1002/ptr.1364 · Cited by 491
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K., Gu, Z.-P., Lee, R., Zhu, Y., Skaar, T., Gomez, B. P., O'Brien, K. A., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 514
Metadata
- Authors
- Writing Group for the Women's Health Initiative Investigators
- Affiliations
- National Heart, Lung, and Blood Institute (US)
- Corresponding author
- Writing Group for the Women's Health Initiative Investigators
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 321-333
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- 1538-3598
- OpenAlex
- W1593442063
- Cited by
- 15,889
- References
- 54
- Citations by year
- 2026: 283 · 2025: 348 · 2024: 342 · 2023: 365 · 2022: 459 · 2021: 465 · 2020: 452 · 2019: 453 · 2018: 455 · 2017: 452 · 2016: 486 · 2015: 572 · 2014: 546 · 2013: 688 · 2012: 713
- FWCI
- 647.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
- Keywords
- estrogen plus progestin, conjugated equine estrogens, medroxyprogesterone acetate, postmenopausal women, hormone replacement therapy, coronary artery disease, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, mortality, benefits and risks, Women's Health Initiative, early trial termination, primary prevention
- MeSH terms
- Aged, Breast Neoplasms, Coronary Disease, Estrogens, Conjugated (USP), Female, Humans, Middle Aged, Myocardial Infarction, Pulmonary Embolism, Risk, Thrombosis, Colorectal Neoplasms, Estrogen Replacement Therapy, Proportional Hazards Models, Survival Analysis, Endometrial Neoplasms, Treatment Outcome, Medroxyprogesterone Acetate, Postmenopause, Stroke, Clinical Trials Data Monitoring Committees, Progesterone Congeners, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
